WuXi XDC Cayman (2268) Stock Overview
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2268 from our risk checks.
2268 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
WuXi XDC Cayman Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$61.15 |
| 52 Week High | HK$85.50 |
| 52 Week Low | HK$24.70 |
| Beta | -0.78 |
| 1 Month Change | 2.69% |
| 3 Month Change | -10.73% |
| 1 Year Change | 111.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 118.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2268 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | 5.1% | 5.8% | 1.6% |
| 1Y | 112.0% | 91.0% | 30.1% |
Return vs Industry: 2268 exceeded the Hong Kong Life Sciences industry which returned 91% over the past year.
Return vs Market: 2268 exceeded the Hong Kong Market which returned 30.1% over the past year.
Price Volatility
| 2268 volatility | |
|---|---|
| 2268 Average Weekly Movement | 7.5% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 2268 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2268's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,662 | Jimmy Li | wuxixdc.com |
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services.
WuXi XDC Cayman Inc. Fundamentals Summary
| 2268 fundamental statistics | |
|---|---|
| Market cap | HK$76.93b |
| Earnings (TTM) | HK$1.69b |
| Revenue (TTM) | HK$6.77b |
Is 2268 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2268 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.94b |
| Cost of Revenue | CN¥3.80b |
| Gross Profit | CN¥2.14b |
| Other Expenses | CN¥658.83m |
| Earnings | CN¥1.48b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.18 |
| Gross Margin | 35.99% |
| Net Profit Margin | 24.91% |
| Debt/Equity Ratio | 7.9% |
How did 2268 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 23:32 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WuXi XDC Cayman Inc. is covered by 37 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| Pei Cheng | China Galaxy Securities Co., Ltd. |